Upcoming trials for DLBCL: R-CHOP with acalabrutinib and obinutuzumab with checkpoint inhibitor
What makes TGR-1202 different from other PI3K inhibitors?
Combining radiotherapy and the immune system in lymphomas
ASH 2017 President’s meeting highlights
Analyzing the affordability of additional multiple myeloma drugs